10 Worst Cancer Stocks To Buy Now According to Short Sellers
Cancer is the second leading cause of death globally, just behind cardiovascular disease, making oncology one of the largest sectors in the life sciences.
Iovance Biotherapeutics Inc. (IOVA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 25,933,142 | $207,983,798 | +35% | 5% |
| 2. | MHR Fund Management Mark Rachesky | 23,997,103 | $192,456,766 | 23.45% | |
| 3. | VenBio Select Advisor Kurt Von Emster | 11,700,000 | $93,834,000 | 1.24% | |
| 4. | Soleus Capital Guy Levy | 7,548,000 | $60,534,960 | +116% | 5.33% |
| 5. | Balyasny Asset Management Dmitry Balyasny | 4,540,560 | $36,415,291 | +279% | 0.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $9.15 | 250,000 | Director | 320,150 | 2024-02-20 | Filing | |
| $9.15 | 32,000 | Director | 54,000 | 2024-02-20 | Filing | |
| $9.15 | 5,000,000 | Director | 28,067,333 | 2024-02-20 | Filing | |
| $5.56 | 10,000 | Director | 248,633 | 2023-09-18 | Filing | |
| $5.30 | 5,000,000 | Director | 23,067,333 | 2023-09-15 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.71 | 20,500 | Director | 100,000 | 2016-08-25 | Filing | |
| $9.10 | 33,500 | Director | 120,500 | 2016-08-24 | Filing | |
| $9.11 | 54,000 | Director | 100,000 | 2016-08-22 | Filing | |
| $7.13 | 16,500 | Director | 154,000 | 2015-09-08 | Filing | |
| $6.84 | 16,000 | Director | 170,500 | 2015-09-04 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 22,812,820 | $185,468,227 | 0% | |
| 2. | 19,071,756 | $155,053,376 | 0% | |
| 3. | 16,424,388 | $133,530,274 | 0% | |
| 4. | 5,263,309 | $42,790,702 | 0.04% | |
| 5. | 5,037,098 | $40,956,054 | 0% |
News See All
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q2 2024 Earnings Call Transcript
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q2 2024 Earnings Call Transcript August 8, 2024Iovance Biotherapeutics, Inc. beats earnings expectations.
Here’s Why Iovance Biotherapeutics (IOVA) Declined in Q2
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” second quarter 2024 investor letter. A copy of the letter can be downloaded here.
10 Most Shorted Stocks That Are Loved by Analysts
Short selling is one of the more controversial ways of making money on the stock market.
Iovance Biotherapeutics (IOVA) Shares Rallied after the FDA approval of AMTAGVI™
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” first quarter 2024 investor letter. A copy of the letter can be downloaded here.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q1 2024 Earnings Call Transcript
Operator: Welcome to the Iovance Biotherapeutics Conference Call to discuss the First Quarter 2024 Results and recent Corporate Updates. My name is Livia, and I'll be your operator for today's call.
5 Best Healthcare Stocks to Buy Under $20
In this article, we will be taking a look at the 5 best healthcare stocks to buy under $20.
Billionaire Paul Tudor Jones and Insiders Love These 10 Stocks
In this article, we will take a detailed look at Billionaire Paul Tudor Jones and Insiders Love These 10 Stocks. For a quick overview of such stocks, read our article Billionaire Paul Tudor Jones and...
5 Best Biotech Stocks To Buy Under $20
In this article, we are going to take a closer look at five best biotech stocks to buy under $20.
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Q4 2023 Earnings Call Transcript
Iovance Biotherapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.45 EPS, expectations were $-0.44. Iovance Biotherapeutics, Inc.
Billionaire Hedge Funds
